- Home
- LSF vs RNXT Comparison
LSF vs RNXT Comparison
Compare LSF & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LSF | RNXT |
|---|---|---|
| Founded | 2015 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.0M | 42.4M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | LSF | RNXT |
|---|---|---|
| Price | $4.71 | $1.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $6.00 | ★ $8.25 |
| AVG Volume (30 Days) | 39.5K | ★ 317.3K |
| Earning Date | 05-06-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 75.28 | 20.00 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $49,889,286.00 | $1,123,000.00 |
| Revenue This Year | $90.82 | $194.66 |
| Revenue Next Year | N/A | $279.78 |
| P/E Ratio | $39.82 | ★ N/A |
| Revenue Growth | 15.23 | ★ 2511.63 |
| 52 Week Low | $1.96 | $0.70 |
| 52 Week High | $6.50 | $1.45 |
Technical Indicators
Market Signals| Indicator | LSF | RNXT |
|---|---|---|
| Relative Strength Index (RSI) | 62.51 | 79.87 |
| Support Level | $2.23 | $0.82 |
| Resistance Level | $5.11 | N/A |
| Average True Range (ATR) | 0.41 | 0.09 |
| MACD | 0.06 | 0.04 |
| Stochastic Oscillator | 89.80 | 98.25 |
Price Performance
Historical ComparisonAbout LSF Laird Superfood Inc.
Laird Superfood Inc is engaged in the development and marketing of food and beverage products focused on health and wellness. The company's product portfolio includes coffee creamers, coffee, tea, hot chocolate, hydration and beverage enhancement products, and snacks, made using natural and functional ingredients.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.